CLINICAL TRIALS

As the breadth of PH research expands, PHA is committed to keeping its members informed about ongoing clinical research pertaining to evaluation and treatment of pulmonary hypertension. One mechanism to achieve this is to provide institutions and other research sponsors who are conducting multi-center clinical trials with an opportunity to describe relevant studies.

Trial Name: Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects wth Pulmonary Arterial HypertensionSponsoring Institution: United Theraputics CorporationPosted August 27, 2013Read More

Trial Name: A Natural History Study of Novel Biomarkers in Pulmonary Arterial HypertensionSponsoring Institution: National Institutes of HealthPosted January 22, 2013Read more

Trial Name: A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial HypertensionSponsoring Institution: National Institutes of HealthPosted January 22, 2013Read more

Trial Name: A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population with Pulmonary Arterial HypertensionSponsoring Institution: Eli Lilly and CompanyPosted July 6, 2012Read more

Trial Name: Determining the Prevalence and Progression of Secondary Pulmonary Hypertension in Adult Patients with Sickle Cell AnemiaSponsoring Institution: National Heart, Lung, and Blood Institute (NHLBI)Posted December 15, 2011Read more

Trial Name: A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).Sponsoring Institution: National Institute of Allergy and Infectious Diseases (NIAID)Posted December 16, 2010Read more

For optimal viewing of PHAssociation.org, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs. PHA does not endorse or recommend any commercial products or services.